BEAM Beam Therapeutics Inc. Common Stock
XNAS
24.90
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BEAM
$24.90
—
Key stats
$24.90
- 52-Week Range
- $20.23 – $38.26
- YTD
- -8.25%
- IV Rank (30D)
- 52.68
- Straddle Price
- $3.80
- P/C Vol Ratio
- 0.26
- Market Cap
- $2.5B
- Open
- $23.73
- Day Range
- $23.39 – $25.09
- Volume
- 2,750,678
- Prev Close
- $23.79
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.67 |
| Cost of Equity (CAPM) | 14.15% (VRP-adj) |
| WACC | 13.95% |
| Volatility Risk Premium | +70.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | -8.0% |
| Book / Price | 48.1% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -227.3% |
| Debt / Equity | 0.09 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $25.96 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $24.58 |
| Bollinger Width / SMA20 | 38.2% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $2B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
99%
20-Day Fair Value
≈ by Nov 25, 2026
$25.29
α +1.5%
rank 97%
conviction
79%
40-Day Fair Value
≈ by Dec 24, 2026
$26.07
α +4.7%
rank 98%
conviction
98%
60-Day Fair Value
≈ by Jan 22, 2027
$26.57
α +6.7%
rank 98%
conviction
99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.5× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.3× · 8 peers |
| Peer P/B | $117.32 | 22% | median 10.2× · 10 peers |
| Peer P/S | $11.64 | 22% | median 6.6× · 9 peers |
| Market Anchor (SMA50) | $25.96 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $23.60 | 56% | 20 strikes · skew -0.15 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $2.5B
- Employees
- 540
- List Date
- 2020-02-06
- CIK
- 0001745999
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- ($1.16) (5 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.beamtx.com
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug cand…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 15.99% | -15.76% | 16.43% | -10.98% | 4.94% | 1.77% | 2.06% |
| Feb | -9.37% | 13.29% | -12.46% | 49.41% | 2.93% | 1.93% | 7.62% |
| Mar | -16.26% | -22.04% | -20.47% | -17.07% | -22.19% | -16.94% | -19.16% |
| Apr | 2.83% | -37.40% | 1.92% | -35.03% | 13.01% | 25.23% | -4.91% |
| May | 4.04% | -13.73% | 3.81% | 9.57% | -20.17% | 7.26% | -1.54% |
| Jun | 65.56% | 13.75% | -1.78% | -3.90% | 5.06% | 10.21% | 14.82% |
| Jul | -31.14% | 58.28% | -3.32% | 37.27% | 12.44% | -23.57% | 8.33% |
| Aug | 22.43% | -7.21% | -18.70% | -11.98% | -13.12% | 13.59% | -2.50% |
| Sep | -22.45% | -14.29% | 2.51% | 0.41% | 48.80% | -15.75% | -0.13% |
| Oct | 2.77% | -8.00% | -1.67% | -6.41% | 3.65% | 2.09%* | -1.26% |
| Nov | -16.24% | 4.13% | 33.46% | 19.36% | 4.45% | -- | 9.03% |
| Dec | 9.65% | -14.66% | -7.95% | -12.35% | 15.26% | -- | -2.01% |
| Total | -3.78% | -52.96% | -18.01% | -10.36% | 44.49% | -4.76% | -7.56% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $24.60
SMA 50: $25.91
SMA 200: $28.23
Current: $24.90
EMA 12: $24.47
EMA 26: $24.80
MACD: -0.3280 | Signal: 0.0821
BEARISH
ADX (14): 9.29
RANGE
+DI: 22.86
−DI: 19.61
Momentum Oscillators
RSI (14): 50.42
NEUTRAL
Stoch %K: 33.62
Stoch %D: 31.89
Williams %R: -43.23
Volume & Volatility
BB Upper: $25.76
BB Lower: $23.44
NEUTRAL
OBV: -6,087,252
Vol SMA 20: 1,755,383
Vol ROC: 64.90%
ATR: $1.29
True Range: $1.70
HV 20: 46.8%
HV 30: 47.6%
HV 60: 58.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall assessment: NEUTRAL with confidence level (5/10) Key drivers and primary risks:
- Recent positive news headlines driving momentum
- High volatility, beta >1.2, indicating high risk
- No earnings data available to assess performance Recent news sentiment impact:
- Positive headlines contributing to upward trend
Technical Analysis Trend Direction: Short-term (1-4 weeks) - Bullish; Medium-term (1-3 months) - Consolidating; Long-term (3-12 months) - Uptrend Support/Resistance Levels: SMA 20 ($28.56), SMA 50 ($29.35), and Bollinger Bands Upper ($31.38) Momentum Signals: RSI interpretation: Neutral (54.25) with no clear buy/sell signal MACD signal: Bullish momentum, with MACD above signal line Bollinger Bands position: Neutral, with price touching middle band Volume Analysis: Volume SMA 20 decreasing (-52.12%), indicating potential selling pressure
News & Sentiment Analysis Recent Headlines Summary: Positive news headlines highlighting Beam Therapeutics' participation in investor conferences and the growth of gene editing therapeutics Sentiment Assessment: Aggregate sentiment is positive (80%) Catalyst Identification: Upcoming investor conferences, FDA approvals, product launches Market Narrative: News aligns with medium-term uptrend
Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta >1.2) Volatility Regime: Current volatility higher than historical levels Options Market Signals: IV rank 27.1% (Medium), Put/Call ratio 2.76 (Bearish sentiment) Downside Protection: Support level at SMA 20 ($28.56) and risk management considerations
Market Context & Positioning Sector Performance: Relative strength within the biotech sector Institutional Activity: Volume patterns suggesting institutional interest Correlation Analysis: Stock moves relatively more than market (R-squared interpretation) Relative Valuation: Position within trading range
Key Levels & Action Items Critical Price Levels:
- SMA 20 ($28.56) - potential support level
- Bollinger Bands Upper ($31.38) - potential resistance level Breakout/Breakdown Levels:
- Short-term breakout above $30.00 could trigger further upside Time-Sensitive Catalysts: Upcoming investor conferences, FDA approvals, product launches Risk Management: Stop-loss levels and position sizing considerations
Additional Notes
- Flag: No earnings data available to assess performance.
- Note: High volatility (beta >1.2) indicating high risk.
- Highlight: Options market pricing $6.38 move by expiration, which could lead to potential profit taking.
- Comment: Recent news headlines driving momentum, but volatility and beta indicate high risk.
Generated
News
All BEAM news →
The gene-editing biotech stock is down more than 12% this year.
Earnings History
23 of 26 under expected move
Avg Expected Move
12.01%
Avg Actual Move
4.61%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-15 | After-Close | 9.07% | 0.73% | 0.08x | Within |
| 2021-05-11 | After-Close | 11.86% | 1.03% | 0.09x | Within |
| 2021-08-10 | After-Close | 12.18% | 3.57% | 0.29x | Within |
| 2021-11-08 | After-Close | 9.99% | 1.37% | 0.14x | Within |
| 2022-01-10 | After-Close | 11.92% | 10.55% | 0.89x | Within |
| 2022-02-28 | After-Close | 15.47% | 6.19% | 0.40x | Within |
| 2022-05-09 | After-Close | 18.35% | 7.48% | 0.41x | Within |
| 2022-08-09 | After-Close | 7.63% | 7.82% | 1.02x | Exceeded |
| 2022-11-07 | After-Close | 13.27% | 1.27% | 0.10x | Within |
| 2023-01-09 | After-Close | 11.89% | 1.99% | 0.17x | Within |
| 2023-02-28 | After-Close | 9.44% | 4.32% | 0.46x | Within |
| 2023-05-10 | After-Close | 9.15% | 1.87% | 0.20x | Within |
| 2023-08-08 | After-Close | 10.29% | 0.53% | 0.05x | Within |
| 2023-11-08 | After-Close | 8.21% | 3.01% | 0.37x | Within |
| 2024-01-08 | After-Close | 15.18% | 0.36% | 0.02x | Within |
| 2024-02-27 | After-Close | 15.98% | 3.24% | 0.20x | Within |
| 2024-05-07 | After-Close | 7.37% | 1.29% | 0.18x | Within |
| 2024-08-06 | After-Close | 11.56% | 4.15% | 0.36x | Within |
| 2024-11-05 | Pre-Market | 13.75% | 1.77% | 0.13x | Within |
| 2025-01-13 | After-Close | 11.55% | 8.77% | 0.76x | Within |
| 2025-05-06 | After-Close | 14.23% | 1.47% | 0.10x | Within |
| 2025-08-05 | After-Close | 10.96% | 2.14% | 0.20x | Within |
| 2025-11-04 | Pre-Market | 17.01% | 6.23% | 0.37x | Within |
| 2026-01-12 | Pre-Market | 10.89% | 22.29% | 2.05x | Exceeded |
| 2026-05-05 | After-Close | 10.55% | 11.90% | 1.13x | Exceeded |
| 2026-08-04 | After-Close | 14.55% | 4.51% | 0.31x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BEAM Options Activity & IV Rank
BEAM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 74.2%
7-DTE IV: —
Expected Move: $3.80
7-DTE Move: $3.80
Days to Exp: 24 (2026-11-20)
Options Flow
Call Volume: 467
Put Volume: 122
P/C Volume: 0.261
BULLISH
Call OI: 4,540
Put OI: 1,711
P/C OI: 0.377
Total OI: 6,251
ATM Options Pricing
ATM Call: $1.57
ATM Put: $2.23
Call %: 6.3%
Put %: 8.9%
Chain Summary
Chain Volume: 1,831
Chain OI: 19,282
Last Updated: 10/27/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
49%
vs own history
GEX tilt
+0.28
OI-weighted, today
Vanna tilt
+0.34
δ-sensitivity to IV
Charm tilt
-0.33
δ-decay vs time
Vanna tilt +0.34: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.33: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 31 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 81.1% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)52.7MediumOct 27
Straddle Price (30 DTE)$3.80Oct 27
Beta Analysis
Risk Metrics
Beta: 2.1078
Alpha: -9.26%
Correlation: 0.3807
R-Squared: 14.5%
Stock Volatility: 70.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BEAM
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $15.3M | #837 of 3138 | -13.4% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $5.3M | #82 of 86 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.2M | #2836 of 3716 | +54.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $140K | #2793 of 4729 | +60.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BEAM Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 101,683,390 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$22.86M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $8.45M | 36.96% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $5.87M | 25.67% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $4.18M | 18.27% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.43M | 10.61% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $1.72M | 7.51% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $226.51K | 0.99% | 2026-06-30 |
5 filers$6.94M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.22M | 46.46% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.39M | 34.39% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $1.05M | 15.14% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $147.58K | 2.13% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $130.42K | 1.88% | 2026-06-30 |
BEAM Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | John M. Evans | CEO | Mixed | — | $12.40 | -$1.14M | EDGAR |
| 2026-10-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell (S) | −187 | $24.41 | -$4.6K | EDGAR |
| 2026-09-25 | Giuseppe Ciaramella | President | Gift (G) | −123,407 | — | EDGAR | |
| 2026-07-29 | Amy Simon | Chief Medical Officer | Sell (S) | −16,667 | $25.74 | -$429.0K | EDGAR |
| 2026-07-02 | Amy Simon | Chief Medical Officer | Sell (S) | −373 | $34.73 | -$13.0K | EDGAR |
| 2026-07-01 | John M. Evans | CEO | Mixed | — | $17.90 | -$1.70M | EDGAR |
| 2026-06-29 | FMR LLC | 10%+ Owner | Sell (S) | −284,860 | $35.24 | -$10.04M | EDGAR |
| 2026-06-22 | Giuseppe Ciaramella | President | Exer (M) | +35,505 | $0.96 | $34.2K | EDGAR |
| 2026-06-05 | Graham K Cooper | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-06-05 | John Maraganore | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-06-05 | Christi Shaw | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-06-05 | Mark Fishman | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-06-05 | Kathleen E Walsh | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-06-05 | Chirfi Guindo | Director | Grant (A) | +19,676 opt | — | EDGAR | |
| 2026-04-06 | Christine Bellon | Chief Legal Officer | Sell (S) | −5,956 | $24.58 | -$146.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BEAM Insider Holdings
8 insiders · @ $24.90
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John M. Evans | CEO | 1,175,205 | $29.26M | -$39.82M | 32 | 2026-10-16 |
| 2 | FMR LLC | 10%+ Owner | 1,106,071 | $27.54M | -$40.83M | 15 | 2026-06-29 |
| 3 | Giuseppe Ciaramella | President | 253,911 | $6.32M | -$28.64M | 35 | 2026-09-25 |
| 4 | Christine Bellon | Chief Legal Officer | 109,711 | $2.73M | -$1.90M | 21 | 2026-04-06 |
| 5 | Sravan Kumar Emany | Chief Financial Officer | 105,456 | $2.63M | -$170.6K | 4 | 2026-04-02 |
| 6 | Amy Simon | Chief Medical Officer | 85,696 | $2.13M | -$2.50M | 18 | 2026-07-29 |
| 7 | Bethany J Cavanagh | SVP, Finance and Treasurer | 50,984 | $1.27M | -$713.8K | 14 | 2026-10-02 |
| 8 | Mark Fishman | Director | 17,007 | $423.5K | $0 | 7 | 2026-06-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BEAM Board & Officers
As of SEC filings through Oct 16, 2026Directors 7
- Graham K Cooper · since Feb 5, 2020
- John M. Evans · since Feb 5, 2020
- Mark Fishman · since Feb 5, 2020
- Kathleen E Walsh · since Jan 10, 2021
- John Maraganore · since Nov 5, 2021
- Christi Shaw · since Dec 13, 2023
- Chirfi Guindo · since Dec 2, 2024
Officers 6
- John M. Evans · CEO · since Feb 5, 2020
- Giuseppe Ciaramella · President · listed since Feb 2024
- Sravan Kumar Emany · Chief Financial Officer · since Dec 19, 2024
- Amy Simon · Chief Medical Officer · since Mar 16, 2023
- Christine Bellon · Chief Legal Officer · since Mar 16, 2023
- Bethany J Cavanagh · SVP, Finance and Treasurer · since Aug 9, 2024
10% owners 1
- Fmr LLC (entity) · listed since Apr 2025
Changes in the last 10 years (45)
| Jan 31, 2026 | The company announced the departure of Carole Ho from the board in an SEC filing |
| Apr 10, 2025 | Fmr LLC first listed as a 10% owner in an SEC filing |
| Dec 19, 2024 | Sravan Kumar Emany became Chief Financial Officer |
| Dec 2, 2024 | Chirfi Guindo became a director |
| Aug 9, 2024 | Bethany J Cavanagh became SVP, Finance and Treasurer |
| Jul 11, 2024 | The company announced the departure of Terry-Ann Burrell as Chief Financial Officer in an SEC filing |
| Feb 15, 2024 | Fmr LLC reported in an SEC filing no longer being a 10% owner |
| Feb 2, 2024 | Giuseppe Ciaramella listed as President (previously President & CSO) in SEC filings |
| Dec 27, 2023 | Fmr LLC first listed as a 10% owner in an SEC filing |
| Dec 13, 2023 | Christi Shaw became a director |
| Mar 16, 2023 | Christine Bellon became Chief Legal Officer |
| Mar 16, 2023 | Amy Simon became Chief Medical Officer |
| Nov 5, 2021 | John Maraganore became a director |
| Jul 2, 2021 | Robert Nelsen reported in an SEC filing no longer being a director |
| Jul 2, 2021 | Robert Nelsen reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | Keith Crandell reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | Clinton Bybee reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | ARCH Venture Partners IX, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | ARCH Venture Partners IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | ARCH Venture Partners IX Overage, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | ARCH Venture Fund IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2021 | ARCH Venture Fund IX Overage, L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 10, 2021 | Kathleen E Walsh became a director |
| Feb 11, 2020 | Redmile Group, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 11, 2020 | Jeremy Green reported in an SEC filing no longer being a 10% owner |
| Feb 5, 2020 | Terry-Ann Burrell became Chief Financial Officer |
| Feb 5, 2020 | Stephen C Knight became a director |
| Feb 5, 2020 | Robert Nelsen became a director |
| Feb 5, 2020 | Robert Nelsen became a 10% owner |
| Feb 5, 2020 | Redmile Group, LLC became a 10% owner |
| Feb 5, 2020 | Mark Fishman became a director |
| Feb 5, 2020 | Kristina Burow became a director |
| Feb 5, 2020 | Keith Crandell became a 10% owner |
| Feb 5, 2020 | John M. Evans became a director |
| Feb 5, 2020 | John M. Evans became CEO |
| Feb 5, 2020 | Jeremy Green became a 10% owner |
| Feb 5, 2020 | Graham K Cooper became a director |
| Feb 5, 2020 | Giuseppe Ciaramella became President & CSO |
| Feb 5, 2020 | Clinton Bybee became a 10% owner |
| Feb 5, 2020 | Carole Ho became a director |
| Feb 5, 2020 | ARCH Venture Partners IX, LLC became a 10% owner |
| Feb 5, 2020 | ARCH Venture Partners IX, L.P. became a 10% owner |
| Feb 5, 2020 | ARCH Venture Partners IX Overage, L.P. became a 10% owner |
| Feb 5, 2020 | ARCH Venture Fund IX, L.P. became a 10% owner |
| Feb 5, 2020 | ARCH Venture Fund IX Overage, L.P. became a 10% owner |
Not reported recently (2)
- Kristina Burow · Last reported as a director in an SEC filing dated Jun 8, 2023
- Stephen C Knight · Last reported as a director in an SEC filing dated Feb 5, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BEAM Proposed Insider Sales (Form 144)
Latest: 2026-10-16
? Form 144 Guide
Last 30d:
2 filings
· $1.2M notice value
· Last 90d:
3 filings
· $1.6M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JOHN M EVANS (2, $1.2M) · AMY SIMON (1, $429K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | JOHN M EVANS | Officer, Director | 25,000 | $599.6K | 2026-10-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-15 | JOHN M EVANS | Officer, Director | 25,000 | $589.1K | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-27 | AMY SIMON | Officer | 16,677 | $429.3K | 2026-07-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-30 | JOHN M EVANS | Officer, Director | 25,000 | $857.7K | 2026-06-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-29 | JOHN M EVANS | Officer, Director | 25,000 | $887.4K | 2026-06-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-14 | CAROLE HO | Director | 87,784 | $2.70M | 2026-04-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-31 | JOHN M EVANS | Officer, Director | 25,000 | $569.1K | 2026-03-31 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-31 | CHRISTINE BELLON | Officer | 20,000 | $438.0K | 2026-04-02 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-03-31 | GIUSEPPE CIARAMELLA | Officer | 26,250 | $574.9K | 2026-04-02 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-03-31 | AMY SIMON | Officer | 20,000 | $438.0K | 2026-04-02 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
82 ETFs hold BEAM
25 shown · $492.78M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.85% | $87.8M | $10.4B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $80.6M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.08% | $60.0M | $74.6B | 2026-10-23 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $56.9M | — | 2026-09-30 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.07% | $31.7M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $27.6M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.15% | $20.0M | $13.7B | 2026-10-23 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.05% | $18.5M | — | 2026-10-23 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.16% | $17.2M | $10.7B | 2026-10-23 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.07% | $15.7M | — | 2026-05-31 |
| 11 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.08% | $14.1M | — | 2026-09-30 |
| 12 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $10.2M | — | 2026-10-23 |
| 13 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.12% | $8.0M | $6.6B | 2026-10-23 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.10% | $7.9M | — | 2026-10-23 |
| 15 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.7M | — | 2026-09-30 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.14% | $4.6M | $3.2B | 2026-10-23 |
| 17 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.13% | $3.5M | — | 2026-06-30 |
| 18 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.12% | $3.4M | — | 2026-07-31 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.59% | $3.4M | — | 2026-10-26 |
| 20 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.3M | $96.5B | 2026-10-23 |
| 21 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $3.2M | — | 2026-10-23 |
| 22 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.14% | $2.4M | — | 2026-09-30 |
| 23 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.2M | $13.9B | 2026-10-23 |
| 24 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.08% | $2.1M | $2.5B | 2026-10-23 |
| 25 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $2.1M | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.50
TTM Revenue
$164.01M
TTM Net Income
$-65.04M
TTM Op. Cash Flow
$-369.73M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $31.74M | $-94.32M | $-0.91 | $-128.51M |
| Q4 '25 | 2025-12-31 | $114.11M | $244.30M | $2.51 | $-83.29M |
| Q3 '25 | 2025-09-30 | $9.70M | $-112.73M | $-1.10 | $-81.48M |
| Q2 '25 | 2025-06-30 | $8.47M | $-102.29M | $-1.00 | $-76.45M |
| Q1 '25 | 2025-03-31 | $7.47M | $-108.33M | $-1.23 | $-103.88M |
| Q4 '24 | 2024-12-31 | $30.07M | $-90.35M | $-1.09 | $-76.36M |
| Q3 '24 | 2024-09-30 | $14.27M | $-96.67M | $-1.17 | $-88.12M |
| Q2 '24 | 2024-06-30 | $11.77M | $-91.05M | $-1.11 | $-83.01M |
| Q1 '24 | 2024-03-31 | $7.41M | $-98.67M | $-1.21 | $-99.75M |
| Q4 '23 | 2023-12-31 | $316.19M | $142.80M | $1.91 | $144.81M |
| Q3 '23 | 2023-09-30 | $17.19M | $-96.09M | $-1.22 | $-89.78M |
| Q2 '23 | 2023-06-30 | $20.12M | $-82.78M | $-1.08 | $-84.67M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.17
P/S
15.44
EV/EBITDA
—
EV/Sales
14.29
ROE
-5.6%
ROA
-4.4%
Div Yield
0.00%
FCF Yield
-14.60%
Debt/Equity
0.09
Current Ratio
—
Market Cap
$2.53B
as of 2026-10-27
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
27.55M
SI % of Float
33.60%
Days to Cover
15.30
Short Vol Ratio
46.9%
Free Float
81.98M
Float %
79.4%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-14